Referências
Principais artigos
World Health Organization. WHO consolidated guidelines on tuberculosis: module 5: management of tuberculosis in children and adolescents. Sep 2022 [internet publication].Texto completo
Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017 Jan 15;64(2):e1-33.Texto completo Resumo
Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016 Oct 1;63(7):e147-95.Texto completo Resumo
World Health Organization. WHO consolidated guidelines on tuberculosis, module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. Dec 2022 [internet publication].Texto completo Resumo
Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2019 Nov 15;200(10):e93-142.Texto completo Resumo
World Health Organization. WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment. Module 1: prevention. 2020 [internet publication].Texto completo
World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment. May 2022 [internet publication].Texto completo
British HIV Association. BHIVA guidelines for the management of tuberculosis in adults living with HIV 2018 (2019 interim update). 2019 [internet publication].Texto completo
National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Mycobacterium tuberculosis infection and disease. Feb 2022 [internet publication].Texto completo
Artigos de referência
1. Polesky A, Grove W, Bhatia G. Peripheral tuberculous lymphadenitis: epidemiology, diagnosis, treatment, and outcome. Medicine (Baltimore). 2005 Nov;84(6):350-62. Resumo
2. Baumann MH, Nolan R, Petrini M, et al. Pleural tuberculosis in the United States: incidence and drug resistance. Chest. 2007 Apr;131(4):1125-32. Resumo
3. Ong A, Creasman J, Hopewell PC, et al. A molecular epidemiological assessment of extrapulmonary tuberculosis in San Francisco. Clin Infect Dis. 2004 Jan 1;38(1):25-31. Resumo
4. World Health Organization. Tuberculosis. 2022 [internet publication].Texto completo
5. World Health Organization. Global tuberculosis report 2022 [internet publication].Texto completo
6. GOV.UK. Tuberculosis in England: annual report. The latest annual report for tuberculosis (TB) in England. Mar 2022 [internet publication].Texto completo
7. Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2021. Nov 2022 [internet publication].Texto completo
8. Gonzalez OY, Adams G, Teeter LD, et al. Extra-pulmonary manifestations in a large metropolitan area with a low incidence of tuberculosis. Int J Tuberc Lung Dis. 2003 Dec;7(12):1178-85. Resumo
9. Yang Z, Kong Y, Wilson F, et al. Identification of risk factors for extrapulmonary tuberculosis. Clin Infect Dis. 2004 Jan 15;38(2):199-205. Resumo
10. European Centre for Disease Prevention and Control. Tuberculosis surveillance and monitoring in Europe 2023 - 2021 data. Mar 2023 [internet publication].Texto completo
11. UK Health Security Agency. Tuberculosis in England, 2022 report (data up to end of 2021). Aug 2023 [internet publication].Texto completo
12. Dye C. Global epidemiology of tuberculosis. Lancet. 2006 Mar 18;367(9514):938-40.Texto completo Resumo
13. GBD 2019 Tuberculosis Collaborators. Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990-2019: results from the Global Burden of Disease Study 2019. Lancet Infect Dis. 2022 Feb;22(2):222-41.Texto completo Resumo
14. Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med. 2004 May 13;350(20):2060-7. Resumo
15. Chow KM, Chow VC, Hung LC, et al. Tuberculous peritonitis-associated mortality is high among patients waiting for the results of mycobacterial cultures of ascitic fluid samples. Clin Infect Dis. 2002 Aug 15;35(4):409-13. Resumo
16. Iseman MD. A clinician's guide to tuberculosis. Baltimore: Lippincott, Williams & Wilkins, 1999.
17. Colditz GA, Brewer TF, Berkley CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. JAMA. 1994 Mar 2;271(9):698-702. Resumo
18. Tobin DM, Roca FJ, Oh SF, et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell. 2012 Feb 3;148(3):434-46.Texto completo Resumo
19. Thuong NTT, Heemskerk D, Tram TTB, et al. Leukotriene A4 hydrolase genotype and HIV infection influence intracerebral inflammation and survival from tuberculous meningitis. J Infect Dis. 2017 Apr 1;215(7):1020-8.Texto completo Resumo
20. Musellim B, Erturan S, Sonmez Duman E, et al. Comparison of extra-pulmonary and pulmonary tuberculosis cases: factors influencing the site of reactivation. Int J Tuberc Lung Dis. 2005 Nov;9(11):1220-3. Resumo
21. Marks SM, Taylor Z, Qualls NL, et al. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med. 2000 Dec;162(6):2033-8.Texto completo Resumo
22. Zuber PL, McKenna MT, Binkin NJ, et al. Long-term risk of tuberculosis among foreign-born persons in the United States. JAMA. 1997 Jul 23-30;278(4):304-7. Resumo
23. Gonzalez OY, Teeter LD, Thanh BT, et al. Extrathoracic tuberculosis lymphadenitis in adult HIV seronegative patients: a population-based analysis in Houston, Texas, USA. Int J Tuber Lung Dis. 2003 Oct;7(10):987-93. Resumo
24. Thwaites G, Chau TT, Mai NT, et al. Tuberculous meningitis. J Neurol Neurosurg Psych. 2000 Mar;68(3):289-99. Resumo
25. Markowitz N, Hansen NI, Hopewell PC, et al. Incidence of tuberculosis in the United States among HIV-infected persons. Ann Intern Med. 1997 Jan 15;126(2):123-32. Resumo
26. Daley CL, Small PM, Schechter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with human immunodeficiency syndrome. N Engl J Med. 1992 Jan 23;326(4):231-5. Resumo
27. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989 Mar 2;320(9):545-50. Resumo
28. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol. 2006 Nov;2(11):602-10. Resumo
29. Jick SS, Lieberman ES, Rahman MU, et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum. 2006 Feb 15;55(1):19-26. Resumo
30. Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004 May 1;38(9):1261-5. Resumo
31. Kamboj M, Sepkowitz KA. The risk of tuberculosis in patients with cancer. Clin Infect Dis. 2006 Jun 1;42(11):1592-5. Resumo
32. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ. 1982;60(4):555-64. Resumo
33. American Thoracic Society (ATS), Centers for Disease Control and Prevention (CDC). Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000 Apr;161(4 pt 2):S221-47.Texto completo Resumo
34. Rieder HL, Snider DE Jr, Cauthen GM, et al. Extrapulmonary tuberculosis in the United States. Am Rev Resp Dis. 1990 Feb;141(2):347-51. Resumo
35. Cantwell MF, McKenna MT, McCray E, et al. Tuberculosis and race/ethnicity in the United States, impact of socioeconomic status. Am J Respir Crit Care Med. 1998 Apr;157(4 Pt 1):1016-20.Texto completo Resumo
36. Nemes E, Geldenhuys H, Rozot V, et al. Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination. N Engl J Med. 2018 Jul 12;379(2):138-49.Texto completo Resumo
37. GOV.UK. BCG vaccination programme. Documents relating to the Bacillus Calmette–Guérin (BCG) vaccination programme. Oct 2021 [internet publication].Texto completo
38. World Health Organization. WHO consolidated guidelines on tuberculosis: module 5: management of tuberculosis in children and adolescents. Sep 2022 [internet publication].Texto completo
39. Centers for Disease Control and Prevention. CDC Yellow Book 2024: health information for international travel. Section 5: travel-associated infections & diseases - tuberculosis. May 2023 [internet publication].Texto completo
40. Centers for Disease Control and Prevention. CDC Yellow Book 2024: health information for international travel. Section 5: travel-associated infections & diseases - perspectives: testing travelers for mycobacterium tuberculosis infection. May 2023 [internet publication].Texto completo
41. Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017 Jan 15;64(2):e1-33.Texto completo Resumo
42. World Health Organization. WHO consolidated guidelines on tuberculosis module 3: diagnosis - rapid diagnostics for tuberculosis detection. Jul 2021 [internet publication].Texto completo
43. Parimon T, Spitters CE, Muangman N, et al. Unexpected pulmonary involvement in extrapulmonary tuberculosis patients. Chest. 2008 Sep;134(3):589-94.Texto completo Resumo
44. Kohli M, Schiller I, Dendukuri N, et al. Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2021 Jan 15;1:CD012768.Texto completo Resumo
45. Kay AW, González Fernández L, Takwoingi Y, et al. Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children. Cochrane Database Syst Rev. 2020 Aug 27;8:CD013359.Texto completo Resumo
46. Bjerrum S, Schiller I, Dendukuri N, et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV. Cochrane Database Syst Rev. 2019 Oct 21;10:CD011420.Texto completo Resumo
47. Nathavitharana RR, Lederer P, Chaplin M, et al. Impact of diagnostic strategies for tuberculosis using lateral flow urine lipoarabinomannan assay in people living with HIV. Cochrane Database Syst Rev. 2021 Aug 20;8:CD014641.Texto completo Resumo
48. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016 Oct 1;63(7):e147-95.Texto completo Resumo
49. Hooper C, Lee YC, Maskell N; BTS Pleural Guideline Group. Investigation of a unilateral pleural effusion in adults. Thorax. 2010 Aug;65 Suppl 2:ii4-17.Texto completo Resumo
50. Kim HJ, Lee Hj, Kwon SY, et al. The prevalence of pulmonary parenchymal tuberculosis in patients with tuberculous pleuritis. Chest. 2006 May;129(5):1253-8. Resumo
51. Siebert AF, Haynes J Jr, Middleton R, et al. Tuberculous pleural effusion: twenty-year experience. Chest. 1991 Apr;99(4):883-6. Resumo
52. Mariconda M,Cozzolino A, Attingenti P, et al. Osteoarticular tuberculosis in a developed country. J Infect. 2007 Apr;54(4):375-80. Resumo
53. Thwaites G, Fisher M, Hemingway C, et al. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect. 2009 Sep;59(3):167-87. Resumo
54. Thwaites GE, Chau TT, Farrar JJ. Improving the bacteriological diagnosis of tuberculous meningitis. J Clin Microbiol. 2004 Jan;42(1):378-9.Texto completo Resumo
55. Lavi R, Yarnitsky D, Rowe JM, et al. Standard vs atraumatic Whitacre needle for diagnostic lumbar puncture: a randomized trial. Neurology. 2006 Oct 24;67(8):1492-4. Resumo
56. Arendt K, Demaerschalk BM, Wingerchuk DM, Camann W. Atraumatic lumbar puncture needles: after all these years, are we still missing the point? Neurologist. 2009 Jan;15(1):17-20. Resumo
57. Nath S, Koziarz A, Badhiwala JH, et al. Atraumatic versus conventional lumbar puncture needles: a systematic review and meta-analysis. Lancet. 2018 Mar 24;391(10126):1197-204. Resumo
58. Rochwerg B, Almenawer SA, Siemieniuk RAC, et al. Atraumatic (pencil-point) versus conventional needles for lumbar puncture: a clinical practice guideline. BMJ. 2018 May 22;361:k1920.Texto completo Resumo
59. Ahmed SV, Jayawarna C, Jude E. Post lumbar puncture headache: diagnosis and management. Postgrad Med J. 2006 Nov;82(973):713-6.Texto completo Resumo
60. Arevalo-Rodriguez I, Ciapponi A, Roqué i Figuls M, et al. Posture and fluids for preventing post-dural puncture headache. Cochrane Database Syst Rev. 2016 Mar 7;(3):CD009199.Texto completo Resumo
61. Riquelme A, Calvo M, Salech F, et al. Value of adenosine deaminase (ADA) in ascitic fluid for the diagnosis of tuberculosis peritonitis: a meta-analysis. J Clin Gastroenterol. 2006 Sep;40(8):705-10. Resumo
62. Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014-48.Texto completo Resumo
63. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53(3):397-417.Texto completo Resumo
64. Bernardi M, Carceni P, Navickis RJ, et al. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 2012 Apr;55(4):1172-81.Texto completo Resumo
65. Aithal GP, Palaniyappan N, China L, et al. Guidelines on the management of ascites in cirrhosis. Gut. 2021 Jan;70(1):9-29.Texto completo Resumo
66. Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol. 2000;32(1):142-53. Resumo
67. Van Hoving DJ, Griesel R, Meintjes G, et al. Abdominal ultrasound for diagnosing abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV-positive individuals. Cochrane Database Syst Rev. 2019 Sep 30;9:CD012777.Texto completo Resumo
68. Elder N. Extrapulmonary tuberculosis. Arch Fam Med. 1992 Sep;1(1):91-8. Resumo
69. Kim JH, Langston AA, Gallis HA. Miliary tuberculosis: epidemiology, clinical manifestations, diagnosis, and outcome. Rev Infect Dis. 1990 Jul-Aug;12(4):583-90. Resumo
70. Crump JA, Reller LB. Two decades of disseminated tuberculosis at a university medical center: the expanding role of mycobacterial blood culture. Clin Infect Dis. 2003 Oct 15;37(8):1037-43. Resumo
71. Maartens G, Willcox, Benatar SR, et al. Miliary tuberculosis: rapid diagnosis, hematologic abnormalities and outcome in 109 treated adults. Am J Med. 1990 Sep;89(3):291-6. Resumo
72. Lee JY. Diagnosis and treatment of extrapulmonary tuberculosis. Tuberc Respir Dis (Seoul). 2015 Apr;78(2):47-55.Texto completo Resumo
73. World Health Organization. WHO consolidated guidelines on tuberculosis: module 3: diagnosis: tests for TB infection. Sep 2022 [internet publication].Texto completo
74. Geldmacher H, Taube C, Kroeger C, et al. Assessment of lymph node tuberculosis in northern Germany: a clinical review. Chest. 2002 Apr;121(4):1177-82. Resumo
75. Shriner KA, Mathisen GE, Goetz MB. Comparison of mycobacterial lymphadenitis among persons infected with human immunodeficiency virus and seronegative controls. Clin Infect Dis. 1992 Oct;15(4):601-5. Resumo
76. Gopi A, Madhaven SM, Sharma SK, et al. Diagnosis and treatment of tuberculous pleural effusion in 2006. Chest. 2007 Mar;131(3):880-9. Resumo
77. Weir MR, Thorton GF. Extrapulmonary tuberculosis: experience of a community hospital and review of the literature. Am J Med. 1992 Oct;15(4):601-5. Resumo
78. Baydur A. The spectrum of extrapulmonary tuberculosis. West J Med. 1977 Apr;126(4):253-62. Resumo
79. Powell DA. Tuberculous lymphadenitis and parotitis. In: Schlossberg D, ed. Tuberculosis and nontuberculous mycobacterial infections, 5th ed. Berkshire, UK: 2006.
80. Jha BC, Dass A, Nagarkar NM, et al. Cervical tuberculous lymphadenopathy: changing clinical pattern and concepts in management. Postgrad Med J. 22001 Mar;77(905):185-7. Resumo
81. Nataraj G, Kurup S, Pandit A, et al. Correlation of fine needle aspiration cytology, smear and culture in tuberculous lymphadenitis: a prospective study. J Postgrad Med. 2002 Apr-Jun;48(2):113-6. Resumo
82. Singh KK, Muralidhar M, Kumar A, et al. Comparison of in house polymerase chain reaction with conventional techniques for the detection of Mycobacterium tuberculosis DNA in granulomatous lymphadenopathy. J Clin Pathol. 2000 May;53(5):355-61. Resumo
83. Field S, Lewis S. Intestinal and peritoneal tuberculosis. In: Rom WN, Garay S, eds. Tuberculosis, 2nd ed. Philadelphia: Lippincott, Williams and Wilkins; 2003.
84. Kirsch CM, Kroe DM, Azzi RL, et al. The optimal number of pleural biopsy specimens for a diagnosis of tuberculous pleurisy. Chest. 1997 Sep;112(3):702-6. Resumo
85. Willcox PA, Potgieter PD, Bateman ED, et al. Rapid diagnosis of sputum negative miliary tuberculosis using the flexible fibreoptic bronchoscope. Thorax. 1986 Sep;41(9):681-4. Resumo
86. Lai KK, Stottmeier KD, Sherman IH, et al. Mycobacterial cervical lymphadenopathy: relationship of etiologic agents to age. JAMA. 1984 Mar 9;251(10):1286-8. Resumo
87. Xu HB, Jiang RH, Li L, et al. Diagnostic value of adenosine deaminase in cerebrospinal fluid for tuberculous meningitis: a meta-analysis. Int J Tuberc Lung Dis. 2010 Nov;14(11):1382-7. Resumo
88. US Preventive Services Task Force. Latent tuberculosis infection in adults: screening. May 2023 [internet publication].Texto completo
89. World Health Organization. WHO consolidated guidelines on tuberculosis: module 2: screening – systematic screening for tuberculosis disease. Mar 2021 [internet publication].Texto completo
90. Mangan JM, Woodruff RS, Winston CA, et al. Recommendations for use of video directly observed therapy during tuberculosis treatment - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023 Mar 24;72(12):313-6.Texto completo Resumo
91. World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment: tuberculosis care and support. Jul 2022 [internet publication].Texto completo
92. World Health Organization. WHO consolidated guidelines on tuberculosis, module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. Dec 2022 [internet publication].Texto completo Resumo
93. Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2019 Nov 15;200(10):e93-142.Texto completo Resumo
94. World Health Organization. Rapid communication: key changes to the treatment of drug-resistant tuberculosis. May 2022 [internet publication].Texto completo
95. World Health Organization. WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment. Module 1: prevention. 2020 [internet publication].Texto completo
96. World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment. May 2022 [internet publication].Texto completo
97. Prasad K, Singh MB, Ryan H. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev. 2016 Apr 28;(4):CD002244.Texto completo Resumo
98. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004 Oct 21;351(17):1741-51. Resumo
99. Wiysonge CS, Ntsekhe M, Thabane L, et al. Interventions for treating tuberculous pericarditis. Cochrane Database Syst Rev. 2017 Sep 13;9(9):CD000526.Texto completo Resumo
100. US Food and Drug Administration. FDA drug safety communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. July 2016 [internet publication].Texto completo
101. European Medicines Agency. Quinolone- and fluoroquinolone-containing medicinal products. Nov 2018 [internet publication].Texto completo
102. US Food & Drug Administraton. FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes. Jul 2018 [internet publication].Texto completo
103. US Food & Drug Administraton. FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. Dec 2018 [internet publication].Texto completo
104. British HIV Association. BHIVA guidelines for the management of tuberculosis in adults living with HIV 2018 (2019 interim update). 2019 [internet publication].Texto completo
105. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Mycobacterium tuberculosis infection and disease. Feb 2022 [internet publication].Texto completo
106. Dorman SE, Nahid P, Kurbatova EV, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med. 2021 May 6;384(18):1705-18.Texto completo Resumo
107. Carr W, Kurbatova E, Starks A, et al. Interim guidance: 4-month rifapentine-moxifloxacin regimen for the treatment of drug-susceptible pulmonary tuberculosis - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022 Feb 25;71(8):285-9.Texto completo Resumo
108. Anyama N, Bracebridge S, Black C, et al. What happens to people diagnosed with tuberculosis? A population-based cohort. Epidemiol Infect. 2007 Oct;135(7):1069-76. Resumo
109. Fielder JF, Chaulk CP, Dalvi M, et al. A high tuberculosis case-fatality rate in a setting of effective tuberculosis control: implications for acceptable treatment success rates. Int J Tuberc Lung Dis. 2002 Dec;6(12):1114-7. Resumo
110. Straetemans M, Glaziou P, Bierrenbach AL, et al. Assessing tuberculosis case fatality ratio: a meta-analysis. PLoS One. 2011 Jun 27;6(6):e20755.Texto completo Resumo
111. Long R, O'Connor R, Palayew M, et al. Disseminated tuberculosis with and without a miliary pattern on chest radiograph: a clinical-pathologic-radiologic correlation. Int J Tuberc Lung Dis. 1997 Feb;1(1):52-8. Resumo
112. Hawkey CR, Yap T, Pereira J, et al. Characterization and management of paradoxical upgrading reactions in HIV-uninfected patients with lymph node tuberculosis. Clin Infect Dis. 2005 May 1;40(9):1368-71. Resumo
113. Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N EnglJ Med. 2010 Jul 15;363(3):257-65.Texto completo Resumo
114. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010 Feb 25;362(8):697-706.Texto completo Resumo
115. Narita M, Ashkin D, Hollender ES, et al. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med. 1998 Jul;158(1):157-61.Texto completo Resumo
116. Cheng V, Ho P, Lee R, et al. Clinical spectrum of paradoxical deterioration during antituberculosis therapy in non-HIV-infected patients. Eur J Clin Microbiol Infect Dis. 2002 Nov;21(11):803-9. Resumo
117. Manosuthi W, Kiertiburanakul S, Phoorisri T, et al. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect. 2006 Dec;53(6):357-63. Resumo
118. Heemskerk AD, Bang ND, Mai NT, et al. Intensified antituberculosis therapy in adults with tuberculous meningitis. N Engl J Med. 2016 Jan 14;374(2):124-34.Texto completo Resumo
119. Mishra R, Patel HK, Singasani R, et al. Tuberculosis septic shock, an elusive pathophysiology and hurdles in management: a case report and review of literature. World J Crit Care Med. 2019 Sep 11;8(5):72-81.Texto completo Resumo
120. Asciak R, Bedawi EO, Bhatnagar R, et al. British Thoracic Society Clinical Statement on pleural procedures. Thorax. 2023 Jul;78(suppl 3):s43-s68.Texto completo Resumo
121. Akram AR, Hartung TK. Intercostal chest drains: a wake-up call from the National Patient Safety Agency rapid response report. J R Coll Physicians Edinb. 2009;39:117-120.Texto completo
122. Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet. 2002 Aug 17;360(9332):528-34. Resumo
123. van Rie A, Warren R, Richardson M, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med. 1999 Oct 14;341(16):1174-9. Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal